
Opinion|Videos|March 24, 2025
Adoption of Emerging Delivery Systems and Future Outlook for NMIBC
Author(s)Karim Chamie, MD, MSHS
An expert discusses how TAR-200 shows promise for non–muscle invasive bladder cancer (NMIBC) treatment, with medical professionals optimistic about its targeted delivery, potentially improved outcomes, and transformative approach to bladder cancer management.
Advertisement
Video content above is prompted by the following:
- How easily can TAR-200 and other emerging delivery systems be adopted into clinical practice for the treatment of NMIBC?
- What are your thoughts on the future outlook for NMIBC?
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves sildenafil oral film for men with erectile dysfunction
2
The UroOnc Minute: Adjuvant Therapy in Renal Cell Carcinoma, with Brian Shuch, MD
3
URO-1 prostate biopsy devices adopted across Novant Health System as clinical study continues
4
Sarah Azari, MD, on early sexual health education for women with bladder cancer
5


